MCID: MLG169
MIFTS: 57

Malignant Astrocytoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Malignant Astrocytoma

MalaCards integrated aliases for Malignant Astrocytoma:

Name: Malignant Astrocytoma 12 74 6
Astrocytoma 44 15
Astrocytoma of Cerebrum 12
Astrocytoma of Brain 12
Cerebral Astrocytoma 12
Astrocytic Tumor 12
Astrocytomas 15
Astroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3069
MeSH 44 D001254
NCIt 50 C4951 C60781
UMLS 71 C0004114 C0750935

Summaries for Malignant Astrocytoma

Disease Ontology : 12 A malignant glioma that is has material basis in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord.

MalaCards based summary : Malignant Astrocytoma, also known as astrocytoma, is related to pilomyxoid astrocytoma and childhood pilocytic astrocytoma. An important gene associated with Malignant Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Dabrafenib and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and endothelial, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Astrocytomas are a type of brain tumor. They originate in a particular kind of glial cells, star-shaped... more...

Related Diseases for Malignant Astrocytoma

Diseases in the Juvenile Astrocytoma family:

Malignant Astrocytoma

Diseases related to Malignant Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 827)
# Related Disease Score Top Affiliating Genes
1 pilomyxoid astrocytoma 33.0 NF1 IDH1 GFAP BRAF ATRX
2 childhood pilocytic astrocytoma 33.0 NF1 IDH1 BRAF
3 pilocytic astrocytoma of cerebellum 32.8 NF1 IDH1 BRAF
4 oligoastrocytoma 32.7 MGMT GFAP
5 glioblastoma 32.7 VEGFA TP53 PTK2 PLAUR PLAU NF1
6 spinal cord astrocytoma 32.7 MGMT IDH1
7 anaplastic astrocytoma 32.6 VEGFA TP53 THBS1 PTK2 PLAUR PLAU
8 mixed oligodendroglioma-astrocytoma 32.5 TP53 MGMT IDH1 ATRX
9 diffuse astrocytoma 32.5 TP53 NF1 MGMT IDH1 GFAP BRAF
10 pilocytic astrocytoma 32.5 TP53 S100B NF1 MGMT IDH1 GFAP
11 adult astrocytic tumour 32.3 TP53 IDH1 ATRX
12 high-grade astrocytoma 31.3 TP53 IDH1 ATRX
13 high grade glioma 31.2 VEGFA TP53 NF1 MGMT ABCB1
14 neurofibromatosis, type i 31.1 TP53 S100B NF1 MGMT IDH1 GFAP
15 medulloblastoma 31.1 VEGFA TP53 S100B NF1 NEURL1 MGMT
16 ganglioglioma 31.0 TP53 S100B NF1 GFAP BRAF
17 craniopharyngioma 31.0 VEGFA NF1 BRAF
18 brain cancer 31.0 VEGFA TP53 THBS1 PLAUR NF1 MGMT
19 vascular cancer 31.0 VEGFA TP53 THBS1
20 giant cell glioblastoma 30.9 TP53 MGMT IDH1 GFAP BRAF ATRX
21 tuberous sclerosis 30.9 VEGFA TP53 S100B NF1 GFAP
22 hemangioblastoma 30.9 VEGFA S100B GFAP
23 pleomorphic xanthoastrocytoma 30.9 TP53 S100B NF1 MGMT IDH1 GFAP
24 astroblastoma 30.9 IDH1 GFAP BRAF
25 melanoma, cutaneous malignant 1 30.8 TP53 NF1 MGMT BRAF
26 desmoplastic infantile ganglioglioma 30.8 GFAP BRAF
27 peripheral nervous system disease 30.8 VEGFA TP53 S100B NF1 GFAP CSF3
28 gliosarcoma 30.8 VEGFA TP53 S100B NF1 MGMT IDH1
29 angiocentric glioma 30.8 S100B IDH1 GFAP
30 diffuse midline glioma, h3 k27m-mutant 30.8 TP53 MGMT IDH1 ATRX
31 fibrosarcoma 30.8 VTN TP53 THBS1 PTK2 PLAUR PLAU
32 myelodysplastic syndrome 30.7 VEGFA TP53 NF1 MGMT IDH1 CSF3
33 gliofibroma 30.7 VTN TP53 NF1 MGMT IDH1 GFAP
34 leiomyosarcoma 30.7 VEGFA TP53 S100B NF1
35 gliomatosis cerebri 30.7 TP53 IDH1 GFAP BRAF
36 nervous system cancer 30.7 TP53 NF1 MGMT IDH1
37 papilloma of choroid plexus 30.7 TP53 S100B GFAP
38 neurofibroma 30.7 VEGFA TP53 S100B NF1
39 mixed glioma 30.7 TP53 NF1 MGMT IDH1 GFAP ATRX
40 brain glioma 30.7 VEGFA TP53 NF1 MGMT IDH1 GFAP
41 atypical teratoid rhabdoid tumor 30.7 TP53 SPP1 S100B GFAP ATRX
42 vitreoretinopathy, neovascular inflammatory 30.7 VTN VEGFA THBS1 GFAP
43 cerebellar astrocytoma 30.7 NF1 IDH1 BRAF
44 li-fraumeni syndrome 30.7 TP53 NF1 IDH1 ATRX
45 optic nerve glioma 30.6 S100B NF1 GFAP
46 cellular ependymoma 30.6 S100B RELA MGMT GFAP
47 gemistocytic astrocytoma 30.6 TP53 S100B IDH1 GFAP ATRX
48 benign ependymoma 30.6 NF1 IDH1 GFAP
49 dysembryoplastic neuroepithelial tumor 30.6 S100B IDH1 GFAP
50 central nervous system cancer 30.6 VEGFA TP53 NF1 MGMT IDH1 GFAP

Graphical network of the top 20 diseases related to Malignant Astrocytoma:



Diseases related to Malignant Astrocytoma

Symptoms & Phenotypes for Malignant Astrocytoma

GenomeRNAi Phenotypes related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.6 BRAF PLAUR
2 Decreased viability GR00055-A-2 9.6 BRAF
3 Decreased viability GR00221-A-1 9.6 NF1 PLAUR PTK2
4 Decreased viability GR00221-A-2 9.6 NF1 PLAUR
5 Decreased viability GR00221-A-4 9.6 BRAF NF1 PLAUR PTK2 THBS1
6 Decreased viability GR00249-S 9.6 BRAF NF1
7 Decreased viability GR00301-A 9.6 BRAF
8 Decreased viability GR00381-A-1 9.6 BRAF
9 Decreased viability GR00386-A-1 9.6 NF1
10 Decreased viability GR00402-S-2 9.6 THBS1

MGI Mouse Phenotypes related to Malignant Astrocytoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 ABCB1 BRAF GFAP IDH1 MGMT NEURL1
2 hematopoietic system MP:0005397 10.42 ABCB1 BRAF CA9 CSF3 IDH1 NF1
3 cardiovascular system MP:0005385 10.4 ABCB1 ATRX BRAF GFAP NF1 PLAU
4 cellular MP:0005384 10.4 ATRX BRAF GFAP NEURL1 NF1 PLAU
5 growth/size/body region MP:0005378 10.4 ABCB1 ATRX BRAF GFAP IDH1 NF1
6 immune system MP:0005387 10.4 ABCB1 BRAF CA9 CSF3 GFAP IDH1
7 behavior/neurological MP:0005386 10.38 ABCB1 ATRX BRAF GFAP NEURL1 NF1
8 endocrine/exocrine gland MP:0005379 10.35 ABCB1 BRAF CA9 MGMT NEURL1 NF1
9 mortality/aging MP:0010768 10.33 ABCB1 ATRX BRAF CA9 GFAP IDH1
10 digestive/alimentary MP:0005381 10.32 ABCB1 BRAF CA9 GFAP NF1 PLAU
11 integument MP:0010771 10.29 BRAF CSF3 NEURL1 NF1 PLAU PTK2
12 liver/biliary system MP:0005370 10.22 ABCB1 BRAF NF1 PLAU PLAUR PTK2
13 nervous system MP:0003631 10.21 ABCB1 ATRX BRAF GFAP MGMT NEURL1
14 muscle MP:0005369 10.17 BRAF GFAP NF1 PLAU PLAUR PTK2
15 neoplasm MP:0002006 10.1 BRAF MGMT NEURL1 NF1 PLAU PTK2
16 limbs/digits/tail MP:0005371 10.04 BRAF NF1 PTK2 RELA THBS1 TP53
17 normal MP:0002873 10.02 BRAF GFAP NEURL1 NF1 PTK2 RELA
18 reproductive system MP:0005389 9.9 ABCB1 ATRX BRAF NEURL1 NF1 PLAU
19 renal/urinary system MP:0005367 9.86 BRAF CSF3 NF1 PLAUR SPP1 THBS1
20 respiratory system MP:0005388 9.73 BRAF IDH1 MGMT NF1 PLAU PLAUR
21 vision/eye MP:0005391 9.32 ATRX BRAF GFAP NF1 PLAU RELA

Drugs & Therapeutics for Malignant Astrocytoma

Drugs for Malignant Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 255)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
2
Trametinib Approved Phase 4 871700-17-3 11707110
3
Tranexamic Acid Approved Phase 3 1197-18-8 5526
4
Hydroxyurea Approved Phase 3 127-07-1 3657
5
Carmustine Approved, Investigational Phase 3 154-93-8 2578
6
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
7
Thioguanine Approved Phase 3 154-42-7 2723601
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Vinblastine Approved Phase 3 865-21-4 13342 241903
10
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
11
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
12
tannic acid Approved Phase 3 1401-55-4
13
Vorinostat Approved, Investigational Phase 2, Phase 3 149647-78-9 5311
14
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
15
Bevacizumab Approved, Investigational Phase 3 216974-75-3
16
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
17
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
18
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
19
Semustine Experimental, Investigational Phase 3 13909-09-6
20 Dianhydrogalactitol Investigational Phase 3 23261-20-3
21 Interferon-alpha Phase 3
22 Hemostatics Phase 3
23 Coagulants Phase 3
24 Antifibrinolytic Agents Phase 3
25 Imatinib Mesylate Phase 3 220127-57-1 123596
26 Pharmaceutical Solutions Phase 3
27 Neurotransmitter Agents Phase 3
28 Anticonvulsants Phase 3
29 Antimitotic Agents Phase 3
30 Tubulin Modulators Phase 3
31 Psychotropic Drugs Phase 3
32 Immunoglobulin G Phase 2, Phase 3
33 Immunoglobulins Phase 2, Phase 3
34 Immunoglobulins, Intravenous Phase 2, Phase 3
35 Antibodies, Monoclonal Phase 2, Phase 3
36 Antibodies Phase 2, Phase 3
37 Endothelial Growth Factors Phase 2, Phase 3
38 Histone Deacetylase Inhibitors Phase 2, Phase 3
39 Mitogens Phase 3
40 Angiogenesis Inhibitors Phase 2, Phase 3
41 Antineoplastic Agents, Immunological Phase 2, Phase 3
42 Trabedersen Phase 3
43
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
44
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
45
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
48
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
49
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 350)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
4 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
5 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
6 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
7 An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
8 A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone Completed NCT00088166 Phase 3 hCRF;placebo hCRF
9 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
10 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
11 A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC) Completed NCT00789828 Phase 3 Everolimus;Placebo
12 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
13 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
14 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
15 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
16 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
17 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
18 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
19 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
20 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
21 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
22 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
23 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Recruiting NCT03633552 Phase 3 Temozolomide
24 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Active, not recruiting NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
25 A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3) Terminated NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
26 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
27 Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. Terminated NCT00761280 Phase 3 trabedersen;temozolomide;carmustine;lomustine
28 A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Terminated NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
29 A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Dexamethasone for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Primary Malignant Glioma Withdrawn NCT00226668 Phase 3 hCRF;placebo hCRF
30 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Withdrawn NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
31 A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
32 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
33 Pediatric Low Grade Astrocytoma: Treatment Guidance Unknown status NCT00005084 Phase 2
34 A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas Unknown status NCT02209428 Phase 2 Temozolomide
35 Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups Unknown status NCT00313521 Phase 2 thiotepa
36 A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
37 Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors Completed NCT00179803 Phase 2
38 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
39 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
40 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
41 Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma) Completed NCT00003621 Phase 2 carmustine;cisplatin;etoposide
42 A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse Completed NCT01068782 Phase 2 XL184
43 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Low Grade Astrocytoma Completed NCT00003468 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
44 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma Completed NCT00003537 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
45 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma Completed NCT00003470 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
47 A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas Completed NCT00004868 Phase 1, Phase 2 semaxanib
48 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
49 Everolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex Completed NCT00411619 Phase 1, Phase 2 Everolimus
50 A Phase I/II Study of Oral Procarbazine in the Treatment of Recurrent High Grade Astrocytomas Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride

Search NIH Clinical Center for Malignant Astrocytoma

Cochrane evidence based reviews: astrocytoma

Genetic Tests for Malignant Astrocytoma

Anatomical Context for Malignant Astrocytoma

MalaCards organs/tissues related to Malignant Astrocytoma:

40
Spinal Cord, Brain, Endothelial, Cerebellum, Pineal, Temporal Lobe, Pituitary

Publications for Malignant Astrocytoma

Articles related to Malignant Astrocytoma:

(show top 50) (show all 11442)
# Title Authors PMID Year
1
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. 61
33484758 2021
2
Is it a new culprit? "TERT promoter mutation" in an aggressive pediatric pilocytic astrocytoma. 61
32813054 2021
3
A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening. 61
33309780 2021
4
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. 61
33524191 2021
5
Diffuse astrocytoma and the diagnostic dilemma of an unusual phenotype: A case report. 61
33304444 2021
6
RNA sequencing data of different grade astrocytoma cell lines. 61
33385022 2021
7
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma. 61
33573473 2021
8
CCND2 amplification is an independent adverse prognostic factor in IDH-mutant lower-grade astrocytoma. 61
33560216 2021
9
Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report-Usage of Immune Checkpoint Inhibition in CMMRD. 61
33535600 2021
10
Preoperative Patient-Reported Outcomes in Suspected Low-Grade Glioma: Markers of Disease Severity and Correlations with Molecular Subtypes. 61
33567561 2021
11
Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity. 61
33606385 2021
12
Illustration of the Added Value of 18F-DOPA PET to Multimodal MRI to Distinguish Low- and High-Grade Gliomas. 61
33577196 2021
13
Noradrenaline protects neurons against H2 O2 -induced death by increasing the supply of glutathione from astrocytes via β3 -adrenoceptor stimulation. 61
32954502 2021
14
The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells. 61
33140310 2021
15
Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas. 61
33191640 2021
16
[Spinal tumors]. 61
33570679 2021
17
Medulloblastoma: Clinical presentation. 61
31494131 2021
18
Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). 61
33585982 2021
19
Intraoperative Consultation in the Diagnosis of Posterior fossa Brain Tumors following the 2016 WHO update. 61
33606311 2021
20
Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoE. 61
32997975 2021
21
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. 61
33589792 2021
22
New molecular prognostic factors of adult diffuse lower-grade gliomas in post-2016 molecular era: a retrospective analysis from single center. 61
33538212 2021
23
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics. 61
32696543 2021
24
The Role of Hypoxia in Glioblastoma Radiotherapy Resistance. 61
33535436 2021
25
Human Galectin-1 in Multiple Cancers: A Privileged Molecular Target in Oncology. 61
33596802 2021
26
Analysis of the P53N a Novel Protein Encoded on Chromosome 22q12.1-12.3 in Glioblastomas and Ependymomas Specimens. 61
33595778 2021
27
Longitudinal Assessment of Enhancing Foci of Abnormal Signal Intensity in Neurofibromatosis Type 1. 61
33541905 2021
28
Whole-Exome Sequencing of Rare Site Endometriosis-Associated Cancer. 61
33557369 2021
29
T2-FLAIR Mismatch Sign and Response to Radiotherapy in Diffuse Intrinsic Pontine Glioma. 61
33535215 2021
30
Isolated cortical tuber in an infant with genetically confirmed tuberous sclerosis complex 1 presenting with symptomatic West syndrome. 61
33181865 2021
31
Immunohistochemical Analysis of DNA Repair- and Drug-Efflux-Associated Molecules in Tumor and Peritumor Areas of Glioblastoma. 61
33562724 2021
32
Long-level intramedullary spinal cord astrocytoma complicated with spine scoliosis: Report of two cases. 61
33485173 2021
33
Adult pilocytic astrocytoma in the molecular era: a comprehensive review. 61
33448230 2021
34
T12 pedicle subtraction osteotomy for post-laminectomy kyphoscoliotic deformity following resection of a thoracolumbar astrocytoma in an adolescent with a previous paraplegic context. 61
32965627 2021
35
Subependymal Giant Cell Astrocytoma in a 79-Year-Old Woman without Clinical Features of Tuberous Sclerosis: A Case Report. 61
33068006 2021
36
Peduncular hallucinosis after debulking of a third ventricular pilocytic astrocytoma: Case report and review of the literature. 61
33339693 2021
37
Partial unilateral lentiginosis with ipsilateral Lisch nodules and pilocytic astrocytoma: Is this a type of segmental neurofibromatosis? 61
33580934 2021
38
Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: a multicenter retrospective case series. 61
33094355 2021
39
Chemotherapy-induced changes in tumor consistency can allow gross total resection of previously unresectable brainstem pilocytic astrocytoma. 61
33500827 2021
40
A comprehensive model including preoperative peripheral blood inflammatory markers for prediction of the prognosis of diffuse spinal cord astrocytoma following surgery. 61
33495960 2021
41
Comparative evaluation of intracranial oligodendroglioma and astrocytoma of similar grades using conventional and T1-weighted DCE-MRI. 61
33469693 2021
42
Desmoplastic infantile astrocytoma and ganglioglioma: a series of 12 patients treated at a single institution. 61
33507362 2021
43
IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology. 61
33432322 2021
44
Giant Cerebellar Ganglioglioma Mimicking a Pilocytic Astrocytoma. 61
33500838 2021
45
Trigeminal nerve chronic motor denervation caused by cerebellar peduncle pilocytic astrocytoma. 61
33479826 2021
46
Dual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma. 61
33448156 2021
47
The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma. 61
33131004 2021
48
Characterization of a new human astrocytoma cell line SHG140: cell proliferation, cell phenotype, karyotype, STR markers and tumorigenicity analysis. 61
33391433 2021
49
Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. 61
33216206 2021
50
A solitary extraventricular subependymal giant cell astrocytoma in the absence of tuberous sclerosis. 61
33250950 2021

Variations for Malignant Astrocytoma

ClinVar genetic disease variations for Malignant Astrocytoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Pathogenic 12364 rs28934574 17:7577094-7577094 17:7673776-7673776
2 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
3 ATRX NM_000489.5(ATRX):c.5579A>G (p.Asn1860Ser) SNV Pathogenic 11724 rs45439799 X:76856021-76856021 X:77600552-77600552

Expression for Malignant Astrocytoma

Search GEO for disease gene expression data for Malignant Astrocytoma.

Pathways for Malignant Astrocytoma

Pathways related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 VTN VEGFA TP53 S100B RELA PTK2
2
Show member pathways
13.31 VEGFA TP53 RELA PTK2 NF1 CSF3
3
Show member pathways
13.31 VTN VEGFA THBS1 SPP1 PTK2 PLAUR
4 12.79 VEGFA TP53 RELA PTK2 BRAF
5
Show member pathways
12.79 VTN VEGFA PTK2 PLAUR PLAU BRAF
6
Show member pathways
12.77 VTN VEGFA THBS1 SPP1 PTK2 BRAF
7 12.72 VEGFA TP53 RELA NF1 BRAF
8
Show member pathways
12.7 VEGFA TP53 RELA PTK2 PLAU BRAF
9
Show member pathways
12.69 VTN VEGFA TP53 THBS1 SPP1 RELA
10
Show member pathways
12.68 VEGFA THBS1 RELA NF1 BRAF
11
Show member pathways
12.65 TP53 RELA PTK2 PLAU BRAF
12
Show member pathways
12.4 VEGFA TP53 RELA PTK2 NF1 BRAF
13 12.38 VEGFA TP53 THBS1 PLAU ABCB1
14 12.2 TP53 RELA PTK2 PLAU
15 12.05 VEGFA TP53 NF1 BRAF
16
Show member pathways
12.04 VEGFA TP53 RELA PTK2 BRAF
17 11.95 VEGFA TP53 RELA PTK2
18
Show member pathways
11.89 VEGFA RELA PTK2 PLAUR PLAU NF1
19
Show member pathways
11.85 TP53 RELA PTK2 BRAF
20 11.82 RELA PTK2 BRAF
21 11.82 TP53 RELA PTK2
22 11.78 TP53 NF1 MGMT BRAF
23 11.74 VEGFA S100B GFAP
24 11.7 VTN PTK2 PLAUR
25 11.63 VEGFA CA9 ABCB1
26 11.63 VEGFA SPP1 PLAU
27 11.6 SPP1 PLAU CSF3
28 11.58 VTN PLAUR PLAU
29 11.58 VTN TP53 THBS1 PLAU BRAF
30 11.57 VEGFA TP53 THBS1 BRAF
31 11.54 VTN VEGFA TP53 THBS1 PTK2 PLAUR
32 11.48 PTK2 NF1 BRAF
33 11.46 VEGFA RELA NF1
34 11.46 VTN PLAUR PLAU
35 11.44 SPP1 PLAUR PLAU
36 11.42 VTN VEGFA SPP1
37
Show member pathways
11.41 SPP1 RELA PLAU
38 10.79 PLAUR PLAU
39 10.75 TP53 ABCB1

GO Terms for Malignant Astrocytoma

Cellular components related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 VTN VEGFA THBS1 SPP1 S100B PLAUR

Biological processes related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 VEGFA THBS1 S100B RELA PTK2 CSF3
2 positive regulation of cell migration GO:0030335 9.8 VEGFA THBS1 PTK2 PLAU
3 regulation of cell proliferation GO:0042127 9.78 TP53 PTK2 PLAU BRAF
4 positive regulation of protein kinase B signaling GO:0051897 9.73 VEGFA THBS1 PTK2 CSF3
5 extracellular matrix organization GO:0030198 9.72 VTN THBS1 SPP1 NF1 GFAP
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 VEGFA PTK2 CSF3
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.69 VEGFA CSF3 BRAF
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.56 VTN VEGFA TP53 CSF3
9 response to hypoxia GO:0001666 9.55 VEGFA THBS1 PLAU NF1 CA9
10 regulation of cell adhesion mediated by integrin GO:0033628 9.52 PTK2 PLAU
11 negative regulation of neuroblast proliferation GO:0007406 9.46 TP53 NF1
12 response to drug GO:0042493 9.43 TP53 THBS1 RELA MGMT CA9 ABCB1
13 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.4 VEGFA TP53
14 negative regulation of apoptotic process GO:0043066 9.23 VEGFA TP53 THBS1 RELA PTK2 PLAUR

Molecular functions related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.76 VEGFA TP53 THBS1 S100B RELA IDH1
2 extracellular matrix binding GO:0050840 9.13 VEGFA THBS1 SPP1
3 integrin binding GO:0005178 9.02 VTN THBS1 SPP1 PTK2 GFAP

Sources for Malignant Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....